Infective Endocarditis (IE) is a clinical entity with high morbidity and mortality despite advances in diagnosis and medical and surgical treatment alternatives. Globally, the prevalence is estimated to be approximately 1.5 cases per 100,000 people, with a mortality rate of 10–30 % [1]. The clinical outcomes of patients with IE exhibit considerable variability, mainly influenced by clinical, microbiological, and treatment characteristics. Heart Failure (HF) can complicate the evolution of patients with IE as a consequence of the structural valvular damage caused by vegetation and other associated lesions.
